Drug intelligence / Profile preview

clomiphene citrate + metformin + chromium picolinate

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy used primarily for treating polycystic ovarian syndrome (PCOS), particularly in women who are resistant to clomiphene citrate alone. This combination targets multiple aspects of PCOS pathophysiology: clomiphene citrate induces ovulation by blocking estrogen receptors in the hypothalamus, metformin improves insulin sensitivity and reduces insulin resistance, and chromium picolinate further enhances insulin sensitivity by decreasing fasting blood sugar and insulin levels.

Other names: clomiphene citrate + metformin + chromium picolinatechromium-Aljazeera Hospital-polycystic ovary syndrome

Targets

ESR2 (ERβ)ND1 (Mitochondrial electron transport chain complex I)ESR1 (ERα)

Beyond the preview

Go deeper on clomiphene citrate + metformin + chromium picolinate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clomiphene citrate + metformin + chromium picolinate.

Explore the full profile